Stay updated with breaking news from Aadi Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Core-Mark Holding Company, Inc....
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CORE, ONDS, ARPO, PFBI; Shareholders are Encouraged to Contact the Firm May 24, 2021 00:43 ET | Source: Halper Sadeh LLP Halper Sadeh LLP North Brunswick, New Jersey, UNITED STATES NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Core-Mark Holding Company, Inc. (NASDAQ: CORE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sa...
Aerpio Pharmaceuticals, Inc. (NasdaqCM:ARPO) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of ARPO with Aadi Bioscience, Inc. If you are an investor, and would like information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Altabancorp (NasdaqCM:ALTA) – Glacier Bancorp, Inc. (NasdaqGS:GBCI) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with ...
Share this article Share this article NEW YORK, May 20, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Ferro Corporation (NYSE: FOE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Prince International Corporation for $22.00 per share in cash. Ondas Holdings Inc. (NASDAQ: ONDS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with American Robotics, Inc. The a...
Home / Top News / Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting LOS ANGELES, May 19, 2021 (GLOBE NEWSWIRE) — Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies...